Thermo Fisher Scientific Inc.

▲ Bull Case

• ◆Clario integration delivers faster than expected ($29-30 adj EPS FY2027E vs. $26.76 base). SaaS-like clinical trial software with sticky revenue; cross-selling through 50% pharma customer base drives $500-700M revenue synergies + >$200M EBITDA by FY2027. If Clario accretion hits $1+/share above base in FY2027, acquisition reprices from 'questionable' to 'transformational'; discount to DHR compresses by half.
• ◆Organic growth re-accelerates to +5-6% FY2027-FY2028 as CDMO capacity utilization recovers, biotech funding stabilizes, and pharma R&D budgets increase. Single quarter of +5%+ organic growth resets growth-vs-value classification and attracts momentum. At 25x FY2028E $35 EPS = $875/share, +94% from current price.
• ◆Governance resolution unlocks $100+/share re-rating. If 2026 Say-on-Pay passes at 70%+ support following LTIP redesign, institutional 'governance discount' lifts. Compression of half the 18x→21x discount on FY2026E $24.88 = $522/share (+16%) with zero EPS change.

▼ Bear Case

• ◆Pharma R&D capex freeze from IRA pressure. Inflation Reduction Act squeezes pharma pricing; top-20 may cut R&D budgets 10-20% in FY2026-2027. With 50% pharma exposure, sustained capex freeze locks organic growth at +1-2% and removes operating leverage thesis for 2-3 years.
• ◆Clario integration overextension + goodwill impairment. Software-intensive clinical trial technology is riskier than PPD/Patheon manufacturing deals. Key personnel departures, technology debt, or competitive pressure from Medidata/Veeva could trigger $2-4B writedown in FY2027-2028, resetting expectations.
• ◆China revenue plateau/decline from 8% (~$3.6B) to 5-6% as local competitors (CSCL, Agilent JV) gain share. Loss of $1-1.5B in above-margin revenue combined with governance overhang could sustain 16-18x multiple discount indefinitely.

“Central question: Is TMO's 18x P/E a temporary opportunity (governance + Clario resolvable) or structural re-rating (ROIC dilution from serial M&A, succession risk, China loss)? Bull side (75% of analysts): 15-25% discount to DHR/A/WAT is entirely from three temporary factors. Serial acquirers of TMO quality trade 22-26x when pipeline is clear; 22x FY2027E = $588, 25x = $669. Buy discount while temporary. Bear side (25%): ROIC stuck at 11.3% vs. WACC 8.5%; peers at 15-30%. Clario adds $9B goodwill on $49B base, pushing goodwill-to-equity >100%. Serial M&A treadmill creates permanent ROI suppression; multiple discount is earned. Our view: Bull case requires governance resolution + Clario delivery. Bear case requires organic stagnation AND Clario failure. Base case—partial governance fix, Clario on plan, 3-5% organic—delivers +43% return over 3 years. Sufficient for ACCUMULATE.”

• ◆Clario acquisition close (regulatory clearance) — Mid-2026; medium impact (expected event, but confirms no surprise)
• ◆2026 Say-on-Pay vote outcome — May/June 2026 annual meeting; HIGH impact (>70% support = governance discount begins compressing)
• ◆Q2 FY2026 earnings (Clario integration commentary) — Aug 2026; HIGH impact (first post-close earnings; integration charges and revenue guidance)
• ◆FY2026 organic growth confirmation — Feb 2027 full-year data; HIGH impact (confirms pharma recovery thesis intact)
• ◆FY2027 adj EPS guidance (Clario accretive year) — Jan 2027; VERY HIGH impact (single most important data point in 3-year thesis)
• ◆China policy normalization or explicit guidance — Any quarter; medium impact (8% revenue; positive commentary could add $50-100/share)

• ◆Pharma R&D capex freeze (IRA + patent cliff) — 20% probability, HIGH impact; monitor pharma company guidance updates and XBI ETF trend
• ◆Clario integration challenges (KS-2) — 8% probability, HIGH impact; watch Q2 FY2026 integration charges vs. guidance
• ◆China revenue deterioration >15% — 10% probability, MEDIUM-HIGH impact; monitor quarterly China organic growth
• ◆2026 Say-on-Pay failure again (KS-3) — 12% probability, MEDIUM impact; key governance reassessment trigger
• ◆CEO Marc Casper departure (KS-5) — 6% probability, MEDIUM-HIGH impact; key person risk for M&A strategy clarity